伊马替尼治疗慢性粒细胞性白血病的疗效观察

目的探讨伊马替尼治疗慢性粒细胞性白血病的近期疗效和安全性。方法应用伊马替尼400～600mg·d-1顿服治疗不同时期的慢性粒细胞性白血病患者18例,评价治疗后的临床疗效和不良反应的发生情况。结果 18例CML患者中11例患者达血液学完全缓解,占61.11%,2例患者血液学部分缓解,总体有效率达到72.22%,临床受益率达83.33%。所有患者均出现一种或多种不良反应,主要包括粒细胞及血小板减少(16.67%)、胃肠道反应(38.89%)、全身水肿(27.78%)、肌肉疼痛或痉挛(33.33%)、低热(16.67%)、皮疹(11.11%)。结论伊马替尼治疗CML患者的近期疗效好,且不良反应轻,可作为无法接受骨髓移植治疗的CML患者的首选化疗药物,但其远期临床疗效尚有待于进一步研究阐明。

--------------

Objective To explore the short-term effects and safety of Imatinib in the treatment of chronic myeloid leukemia(CML). Methods In this study, 18 patients within different clinical stages of CML were administrated with 400～600 mg·d-1 Imatinib. Blood routine test and, knochenbild myelogramm were performed, Ph chromosome and BCR-ABL fusion gene were detected before and after treatment, and the curative effects and adverse reaction were assessed after treatment. Results Among the 18 cases of CML patients, 11 of them achieved hematologic complete remission, accounting for 61.11%, and two of them got hematological partial remission. The total efficiency was 72.22%, and total clinical benefit rate was 83.33%. Adverse effects were observed in all the patients, including granulocytopenia and thrombocytopenia (16.67%), gastrointestinal reaction(38.89%), hyposarca(27.78%), muscle pain or spasm(33.33%), thrombocytopenia(5.56%), low fever(16.67%) and rash(11.11%). Conclusion Imatinib treatment had good short-term effects and mild light adverse effects on CML patients. It could be used as the preferred chemotherapy drug for those CML patients who could not be treated with bone marrow transplantation. But further research is still required to investigate the long-term efficacy.